Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NF-kappa-B inhibitor alpha (IκBα) is a key regulatory protein that controls the activity of the NF-kappa-B transcription factor, a central mediator of inflammation and immune responses [1, 11]. In unstimulated cells, IκBα binds to NF-kappa-B dimers in the cytoplasm, masking their nuclear localization signals and preventing their translocation to the nucleus [1, 2]. Upon cellular stimulation by cytokines or pathogens, IκBα is phosphorylated by the IκB kinase (IKK) complex, which triggers its ubiquitination and subsequent degradation by the 26S proteasome [11, 15]. The loss of IκBα allows NF-kappa-B to enter the nucleus and initiate the transcription of various pro-survival and pro-inflammatory genes [11]. Dysregulation of this process, through mutations or excessive degradation of IκBα, is linked to chronic inflammatory diseases, autoimmune disorders, and various cancers, including Hodgkin's lymphoma and leukemia [1, 5, 8]. Therapeutic strategies involving this target focus on preventing IκBα degradation using proteasome inhibitors or IKK inhibitors to maintain NF-kappa-B in an inactive state [3, 4, 10]. Additionally, experimental therapies utilize "super-repressor" versions of IκBα that are resistant to degradation to achieve more targeted pathway inhibition [16, 17].
Drugs typically modulate this target by preventing its phosphorylation via IKK inhibition or its degradation via proteasome inhibition, which stabilizes the IκBα/NF-kappa-B complex in the cytoplasm. This stabilization prevents nuclear translocation of NF-kappa-B and subsequent transcription of pro-inflammatory and anti-apoptotic genes. Experimental approaches also include the direct delivery of degradation-resistant "super-repressor" variants of the protein.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NF-kappa-B inhibitor alpha (IκBα) (IκBα).